Literature DB >> 22581376

Evaluation of multifocal visual evoked potentials in patients with Graves' orbitopathy and subclinical optic nerve involvement.

Consuelo Pérez-Rico1, Natividad Rodríguez-González, Juan Arévalo-Serrano, Román Blanco.   

Abstract

Dysthyroid optic neuropathy is the most serious, although infrequent (8-10 %) complication in Graves' orbitopathy (GO). It is known that early stages of compressive optic neuropathy may produce reversible visual field defects, suggesting axoplasmic stasis rather than ganglion cell death. This observational, cross-sectional, case-control study assessed 34 consecutive patients (65 eyes) with Graves' hyperthyroidism and longstanding GO and 31 age-matched control subjects. The patients' multifocal visual evoked potentials (mfVEP) were compared to their clinical and psychophysical (standard automated perimetry [SAP]) and structural (optic coherence tomography [OCT]) diagnostic test data. Abnormal cluster defects were found in 12.3 % and 3.1 % of eyes on the interocular and monocular amplitude analysis mfVEP probability plots, respectively. As well, mfVEP latencies delays were found in 13.8 and 20 % of eyes on the interocular and monocular analysis probability plots, respectively. Interestingly, 19 % of patients with GO had ocular hypertension, and a strong correlation between intraocular pressure measured at upgaze and mfVEP latency was found. MfVEP amplitudes and visual acuity were significantly related to each other (P < 0.05), but not with the latencies delays. However, relationships between the interocular or monocular mfVEP amplitudes and latencies analysis and SAP indices or OCT data were not statistically significant. One-third of our patients with GO showed changes in the mfVEP, indicating significant subclinical optic nerve dysfunction. In this sense, the mfVEP may be a useful diagnostic tool in the clinic for early diagnosis and monitoring of optic nerve function abnormalities in patients with GO.

Entities:  

Mesh:

Year:  2012        PMID: 22581376     DOI: 10.1007/s10633-012-9325-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  39 in total

Review 1.  Multifocal VEP and ganglion cell damage: applications and limitations for the study of glaucoma.

Authors:  Donald C Hood; Vivienne C Greenstein
Journal:  Prog Retin Eye Res       Date:  2003-03       Impact factor: 21.198

2.  Determining abnormal interocular latencies of multifocal visual evoked potentials.

Authors:  Donald C Hood; Xian Zhang; Christopher Rodarte; E Bo Yang; Nitin Ohri; Brad Fortune; Chris A Johnson
Journal:  Doc Ophthalmol       Date:  2004-09       Impact factor: 2.379

3.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

4.  Optic nerve involvement in dysthyroidism.

Authors:  J D Trobe
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

5.  Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.

Authors:  David McKeag; Carol Lane; John H Lazarus; Lelio Baldeschi; Kostas Boboridis; A Jane Dickinson; A Iain Hullo; George Kahaly; Gerry Krassas; Claudio Marcocci; Michele Marinò; Maarten P Mourits; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Petros Perros; Aldo Pinchera; Susanne Pitz; Mark F Prummel; Maria S Sartini; Wilmar M Wiersinga
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

6.  Normative ranges and specificity of the multifocal VEP.

Authors:  Brad Fortune; Xian Zhang; Donald C Hood; Shaban Demirel; Chris A Johnson
Journal:  Doc Ophthalmol       Date:  2004-07       Impact factor: 2.379

7.  [Intraocular high pressure in thyroid-associated orbitopathy: physiopathological mechanisms, diagnosis, and management. Three case reports].

Authors:  H Ben Ayed; M Hamedani; C Bok; P Barraco; A Oubaaz; S Morax
Journal:  J Fr Ophtalmol       Date:  2002-01       Impact factor: 0.818

8.  Subclinical optic neuropathy in Graves' orbitopathy.

Authors:  Gölge Acaroğlu; Tülay Simşek; Solmaz Ozalp; Ayşe Mutluay
Journal:  Jpn J Ophthalmol       Date:  2003 Sep-Oct       Impact factor: 2.447

9.  Central and peripheral nerve conduction in thyroid dysfunction: the influence of L-thyroxine therapy compared with warming upon the conduction abnormalities of primary hypothyroidism.

Authors:  R J Abbott; B P O'Malley; D B Barnett; L Timson; F D Rosenthal
Journal:  Clin Sci (Lond)       Date:  1983-06       Impact factor: 6.124

10.  Repeat reliability of the multifocal visual evoked potential in normal and glaucomatous eyes.

Authors:  Candice S Chen; Donald C Hood; Xian Zhang; Emely Z Karam; Jeffrey M Liebmann; Robert Ritch; Phamornsak Thienprasiddhi; Vivienne C Greenstein
Journal:  J Glaucoma       Date:  2003-10       Impact factor: 2.503

View more
  4 in total

1.  Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.

Authors:  K A Ponto; T Diana; H Binder; N Matheis; S Pitz; N Pfeiffer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-03-04       Impact factor: 4.256

2.  Early macular and peripapillary vasculature dropout in active thyroid eye disease.

Authors:  Mansoreh Jamshidian Tehrani; Zahra Mahdizad; Abolfazl Kasaei; Masoud Aghsaei Fard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-23       Impact factor: 3.117

3.  Electrophysiological Studies in Thyroid Associated Orbitopathy: A Systematic Review.

Authors:  Tiara W U Iao; Shi Song Rong; An Ni Ling; Mårten E Brelén; Alvin Lerrmann Young; Kelvin K L Chong
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

4.  A Pilot Study of Subclinical Non-Capillary Peripapillary Perfusion Changes in Thyroid-Related Orbitopathy Detected Using Optical Coherence Tomography Angiography.

Authors:  Alexander Pinhas; Jorge S Andrade Romo; Giselle Lynch; Davis B Zhou; Maria V Castanos Toral; Phillip A Tenzel; Oscar Otero-Marquez; Shoshana Yakubova; Alexander Barash; David Della Rocca; Robert Della Rocca; Toco Y P Chui; Richard B Rosen; Harsha S Reddy
Journal:  Clin Ophthalmol       Date:  2022-03-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.